Extracellular matrix cancer vaccine adjuvant



Compositions suitable for use as adjuvants in the preparation of vaccines, particularly those vaccines useful in the treatment of cancer, are provided. Methods for inhibiting tumor growth in an animal are also disclosed. Methods for immunizing an animal against cancer, such as prostate cancer, are also described. The adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), trocar, or other solid or semi-solid preparation. The invention provides for enhanced tumor inhibition of 2-fold or greater, compared to vaccine preparations without the extracellular matrix material, or from 4- to 5-fold, compared to preparations without the adjuvant promoting extracellular materials.


Attribute NameValues
  • Extracellular matrix cancer vaccine adjuvant

Patent Number
  • US 8802113 B2

  • Mark A. Suckow

  • William R. Wolter

Inventor From Local Institution
  • Mark A. Suckow

  • William R. Wolter

Other Application
  • 11/875,698

Prior Publication Date
  • 2008-10-23

Prior Publication Number
  • US 20080260800 A1

  • 16

Classification (US Patent)
  • 424/277.1; 424/423; 424/443; 424/484; 424/489

Cooperative Patent Classification codes
  • A61K 35/52 (20130101); A61K 39/0005 (20130101); A61K 2039/585 (20130101)

International Patent Classification codes
  • A61K 9/00 (20060101); A61K 9/14 (20060101); A61K 9/70 (20060101)

  • English

Date Issued
  • 2014-08-12

  • U.S. Patent and Trademark Office

  • University of Notre Dame du Lac

Record Visibility Public
Content License
  • All rights reserved

Departments and Units
Member of


Collections Featuring this Patent
Notre Dame Patents


Please Note: You may encounter a delay before a download begins. Large or infrequently accessed files can take several minutes to retrieve from our archival storage system.